Geng DY, Chen QS, Chen WX, Zhou LS, Han XS, Xie QH, Guo GH, Chen XF, Chen JS, Zhong XP. Molecular targets and mechanisms of different aberrant alternative splicing in metastatic liver cancer. World J Clin Oncol 2024; 15(4): 531-539 [PMID: 38689626 DOI: 10.5306/wjco.v15.i4.531]
Corresponding Author of This Article
Xiao-Ping Zhong, PhD, Professor, Department of Plastic and Burns Surgery, The Second Affiliated Hospital of Shantou University Medical College, Dongxia North Road, Shantou 515000, Guangdong Province, China. zhongxiaoping@stu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
De-Yi Geng, Qing-Shan Chen, Wan-Xian Chen, Lin-Sa Zhou, Xiao-Sha Han, Qi-Hu Xie, Geng-Hong Guo, Xue-Fen Chen, Jia-Sheng Chen, Xiao-Ping Zhong, Department of Plastic and Burns Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515000, Guangdong Province, China
De-Yi Geng, Qing-Shan Chen, Wan-Xian Chen, Lin-Sa Zhou, Xiao-Sha Han, Qi-Hu Xie, Geng-Hong Guo, Xue-Fen Chen, Jia-Sheng Chen, Xiao-Ping Zhong, Plastic Surgery Research Institute, Ear Deformities Treatment Center and Cleft Lip and Palate Treatment Center of Shantou University Medical College, Shantou 515000, Guangdong Province, China
Co-first authors: De-Yi Geng and Qing-Shan Chen.
Co-corresponding authors: Jia-Sheng Chen and Xiao-Ping Zhong.
Author contributions: Chen JS and Zhong XP participated in the study selection; Geng DY, Chen QS, Chen WX and Zhou LS wrote the main manuscript and edited each part of the manuscript; Han XS and Xie QH are responsible for literature research; Guo GH, Chen XF and Zhong XP participated in the comprehensive analysis and finalization. All authors were involved in drafting, reviewing, approving and deciding whether to publish the first draft.
Supported bythe National Natural Science Foundation of China, No. 82002068 and No. 82272281; and the Natural Science Foundation of Guangdong Province, No. 2021A1515010949.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Ping Zhong, PhD, Professor, Department of Plastic and Burns Surgery, The Second Affiliated Hospital of Shantou University Medical College, Dongxia North Road, Shantou 515000, Guangdong Province, China. zhongxiaoping@stu.edu.cn
Received: December 27, 2023 Peer-review started: December 27, 2023 First decision: January 15, 2024 Revised: January 29, 2024 Accepted: March 7, 2024 Article in press: March 7, 2024 Published online: April 24, 2024 Processing time: 116 Days and 17 Hours
Abstract
Metastasis remains a major challenge in the successful management of malignant diseases. The liver is a major site of metastatic disease and a leading cause of death from gastrointestinal malignancies such as colon, stomach, and pancreatic cancers, as well as melanoma, breast cancer, and sarcoma. As an important factor that influences the development of metastatic liver cancer, alternative splicing drives the diversity of RNA transcripts and protein subtypes, which may provide potential to broaden the target space. In particular, the dysfunction of splicing factors and abnormal expression of splicing variants are associated with the occurrence, progression, aggressiveness, and drug resistance of cancers caused by the selective splicing of specific genes. This review is the first to provide a detailed summary of the normal splicing process and alterations that occur during metastatic liver cancer. It will cover the role of alternative splicing in the mechanisms of metastatic liver cancer by examining splicing factor changes, abnormal splicing, and the contribution of hypoxia to these changes during metastasis.
Core Tip: Metastatic liver cancer refers to tumors formed outside the liver that metastasize to the liver and colonize it. Abnormal alternative splicing is a molecular characteristic unique to almost all tumor types. Most tumors exhibit a wide range of splicing abnormalities compared to the surrounding healthy tissues. This review is the first to provide a detailed summary of the normal splicing process and alterations that occur during metastatic liver cancer by examining splicing factor changes, abnormal splicing, and the contribution of hypoxia to cellular changes.
